308 related articles for article (PubMed ID: 33246930)
41. Identifying factors associated with hypoglycemia-related hospitalizations among elderly patients with T2DM in the US: a novel approach using influential variable analysis.
Fu H; Xie W; Curtis B; Schuster D
Curr Med Res Opin; 2014 Sep; 30(9):1787-93. PubMed ID: 24810150
[TBL] [Abstract][Full Text] [Related]
42. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Cahn A; Melzer-Cohen C; Pollack R; Chodick G; Shalev V
Diabetes Obes Metab; 2019 Feb; 21(2):340-348. PubMed ID: 30207040
[TBL] [Abstract][Full Text] [Related]
43. Non-severe Hypoglycemia Risk Difference between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2-I) as an Add-On to Metformin in Randomized Controlled Trials.
Farahani P
J Popul Ther Clin Pharmacol; 2017 May; 24(2):e32-e40. PubMed ID: 28594482
[TBL] [Abstract][Full Text] [Related]
44. Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care.
Tanaka A; Node K
Cardiovasc Diabetol; 2020 Sep; 19(1):132. PubMed ID: 32878601
[TBL] [Abstract][Full Text] [Related]
45. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
[TBL] [Abstract][Full Text] [Related]
46. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
Koh ES; Han K; Nam YS; Wittbrodt ET; Fenici P; Kosiborod MN; Heerspink HJL; Yoo SJ; Kwon HS
Diabetes Obes Metab; 2021 Feb; 23(2):455-466. PubMed ID: 33118320
[TBL] [Abstract][Full Text] [Related]
47. Real-world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score-matched model analysis in Japan.
Horii T; Oikawa Y; Shimada A; Mihara K
J Diabetes Investig; 2023 Nov; 14(11):1262-1267. PubMed ID: 37517084
[TBL] [Abstract][Full Text] [Related]
48. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.
Fralick M; Redelmeier DA; Patorno E; Franklin JM; Razak F; Gomes T; Schneeweiss S
J Gen Intern Med; 2021 Sep; 36(9):2601-2607. PubMed ID: 33564942
[TBL] [Abstract][Full Text] [Related]
49. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H; Vallon V
Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
[TBL] [Abstract][Full Text] [Related]
50. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Vivian E
Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
[TBL] [Abstract][Full Text] [Related]
51. Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations.
Alshnbari A; Alkharaiji M; Anyanwagu U; Idris I
Curr Med Res Opin; 2020 Dec; 36(12):1985-1989. PubMed ID: 33085525
[TBL] [Abstract][Full Text] [Related]
52. Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users.
Jong GP; Lin TK; Liao PL; Huang JY; Yang TY; Pan LF
Transl Stroke Res; 2023 Jul; ():. PubMed ID: 37442919
[TBL] [Abstract][Full Text] [Related]
53. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
54. Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk.
Hu WS; Lin CL
J Diabetes Complications; 2023 May; 37(5):108468. PubMed ID: 37043985
[TBL] [Abstract][Full Text] [Related]
55. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
[TBL] [Abstract][Full Text] [Related]
56. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
[TBL] [Abstract][Full Text] [Related]
57. SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes.
Wang F; Hendryx M; Liu N; Bidulescu A; Mitra AK; Luo J
Drug Saf; 2024 Feb; 47(2):125-133. PubMed ID: 38070101
[TBL] [Abstract][Full Text] [Related]
58. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
59. Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study.
Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
BMJ Open Diabetes Res Care; 2021 Dec; 9(2):. PubMed ID: 34906925
[TBL] [Abstract][Full Text] [Related]
60. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
